The Depression, Anxiety and Stress Scale (DASS-21) as a Screener for Depression in Substance Use Disorder Inpatients: A Pilot Study

Depression is a common co-morbid disorder in substance use disorder (SUD) patients. Hence, valid instruments are needed to screen for depression in this subpopulation. In this study, the predictive validity of the Depression, Anxiety and Stress Scale (DASS-21) for the presence of a depressive disorder was investigated in SUD inpatients. Furthermore, differences between DASS-21 scores at intake and those recorded one week after inpatient detoxification were assessed in order to determine the measurement point of the assessment of the DASS-21 leading to the best predictive validity. The DASS-21 was administered to 47 patients at intake and shortly after inpatient detoxification. The results of the DASS-21 were compared to the Mini International Neuropsychiatric Interview (MINI), which served as the gold standard. Levels of sensitivity and specificity of 78–89% and 71–76% were found for the DASS-21 assessed after detoxification, satisfactorily predicting depression as diagnosed with the MINI. Total DASS-21 scores as well as the DASS subscale for depression were significantly reduced at the second measurement, compared to the DASS at intake. We conclude that the DASS-21 may be a suitable instrument to screen for depressive disorders in SUD patients when administered (shortly) after detoxification. Future research is needed to support this conclusion.

[1]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[2]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[3]  A. Osman,et al.  The Depression Anxiety Stress Scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates. , 2012, Journal of clinical psychology.

[4]  D. Mossman,et al.  Tests of a symptom checklist to screen for comorbid psychiatric disorders in alcoholism. , 2006, Comprehensive psychiatry.

[5]  U. Malt,et al.  Comorbid mental disorders in substance users from a single catchment area - a clinical study , 2011, BMC psychiatry.

[6]  G. Altoé,et al.  The Italian version of the Depression Anxiety Stress Scales-21: Factor structure and psychometric properties on community and clinical samples. , 2015, Comprehensive psychiatry.

[7]  D. Kissane,et al.  Demoralization in Patients With Substance Use and Co-Occurring Psychiatric Disorders , 2017, Journal of dual diagnosis.

[8]  D S Rae,et al.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. , 1990, JAMA.

[9]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[10]  J. Vasconcelos-Raposo,et al.  Factor Structure and Reliability of the Depression, Anxiety and Stress Scales in a Large Portuguese Community Sample , 2013, The Spanish Journal of Psychology.

[11]  L. Najavits,et al.  Screening of Current Post-Traumatic Stress Disorder in Patients with Substance Use Disorder Using the Depression, Anxiety and Stress Scale (DASS-21): A Reliable and Convenient Measure , 2014, European Addiction Research.

[12]  Kareen N. Tonsing.  Psychometric properties and validation of Nepali version of the Depression Anxiety Stress Scales (DASS-21). , 2014, Asian journal of psychiatry.

[13]  F. Cosci,et al.  The Use of the Diagnostic Criteria for Psychosomatic Research in Substance Use Disorder Patients , 2013, Psychotherapy and Psychosomatics.

[14]  G. Fava,et al.  Demoralization: a systematic review on its clinical characterization , 2014, Psychological Medicine.

[15]  K. Brady,et al.  Mood Disorders and Substance Use Disorder: A Complex Comorbidity , 2005, Science & practice perspectives.

[16]  S. J. Sinclair,et al.  Psychometric Evaluation and Normative Data for the Depression, Anxiety, and Stress Scales-21 (DASS-21) in a Nonclinical Sample of U.S. Adults , 2012, Evaluation & the health professions.

[17]  W. van den Brink,et al.  Feasibility and validity of low-budget telephonic follow-up interviews in routine outcome monitoring of substance abuse treatment. , 2009, Addiction.

[18]  P. Vaglum,et al.  Axis I and II disorders as long-term predictors of mental distress: a six-year prospective follow-up of substance-dependent patients , 2007, BMC psychiatry.

[19]  P. Lovibond,et al.  Manual for the Depression Anxiety Stress Scales. 2 , 1995 .

[20]  J. Henry,et al.  The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. , 2005, The British journal of clinical psychology.

[21]  M. Antony,et al.  Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. , 1998 .

[22]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[23]  J. Fisher,et al.  Validation of the depression anxiety stress scales (DASS) 21 as a screening instrument for depression and anxiety in a rural community-based cohort of northern Vietnamese women , 2013, BMC Psychiatry.

[24]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[25]  J. McAuley,et al.  The Depression Anxiety Stress Scale (DASS). , 2010, Journal of physiotherapy.